Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tuvonralimab/Iparomlimab + GEMOX in Biliary Tract Cancer
NCT07267078Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuvonralimab and iparomlimab in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Primary endpoint: R0 Resection Rate. Started May 2025; status: recruiting.
02
Drugs
tuvonralimabiparomlimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07267078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07267078.